Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
  • 0 views
  • 29 Dec, 2021
  • 1 location
Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.

-ventricular systolic dysfunction (either ICM or NICM) and ventricular scar/fibrosis on cardiovascular magnetic resonance are randomized to either ICD or implantable loop recorder (ILR) insertion and are

angiotensin
left ventricular systolic dysfunction
sudden cardiac death
beta-adrenergic blocking agents
ejection fraction
  • 84 views
  • 26 Jan, 2021
  • 20 locations
Long-term Beta-blocker Therapy After Acute Myocardial Infarction (SMART-DECISION)

(HF) or left ventricular systolic dysfunction after acute myocardial infarction (AMI). Prospective, open-label, randomized, multicenter, noninferiority trial to determine

myocardial infarction
infarct
acute myocardial infarction
beta blockers
heart failure
  • 0 views
  • 25 May, 2022
  • 1 location
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy

evidence is still needed. This is a multi-center, double-blind, randomized, placebo-controlled study that aims to establish the efficacy of carvedilol for the primary prevention of left ventricular

treatment regimen
anthracyclines
primary cancer
  • 0 views
  • 08 Oct, 2021
  • 1 location
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, …

cytarabine/daunorubicin
daunorubicin
mitoxantrone
cell transplantation
methotrexate
  • 141 views
  • 10 May, 2022
  • 98 locations
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion (ADAPT)

Sepsis induces both a systolic and diastolic cardiac dysfunction. The prevalence of this septic cardiomyopathy ranges between 30 and 60% according to the timing of assessment and definition used. Although the prognostic role of septic cardiomyopathy remains debated, sepsis-induced left ventricular (LV) systolic dysfunction may be severe and associated with …

levosimendan
septic shock
norepinephrine
ejection fraction
resuscitation
  • 0 views
  • 24 Mar, 2022
  • 15 locations
Aerobic Physical Exercise is Cardio-protective in Subjects With Hemato-oncological Disease and New-onset Chemotherapy (AEROHEMONCO)

least 3 months, in subjects with lymphoma and new-onset chemotherapy, is effective in preventing left ventricular systolic dysfunction, at the end of chemotherapy and at one year. For this, the

  • 0 views
  • 20 Aug, 2022
  • 1 location
Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation (RAFT-PermAF)

Atrial fibrillation (AF) and heart failure (HF) are two common heart conditions that are encountered with an increase in death and suffering. When both these two conditions occur in a patient, the patient's prognosis is poor with a reduced quality of life and impaired heart function. These patients have enlarged …

atrial fibrillation
permanent atrial fibrillation
cardioversion
edema
cardiac death
  • 77 views
  • 11 Apr, 2022
  • 13 locations
Lokelma for RAAS Maximisation in CKD & Heart Failure. (LIFT)

Background: CKD in patients with heart failure (HF) is common and associated with poor prognosis. Despite evidence of benefit with Renin-Angiotensin-Aldosterone-System inhibitor (RAASi) agents, they are avoided due to fear of hyperkalaemia. New potassium binders, e.g. Sodium Zirconium Cyclosilicate (SZC), reduce incidence of hyperkalaemia in CKD-HF patients and hence may …

aldosterone
heart failure
  • 0 views
  • 14 Mar, 2022
Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation (FASTRHAC)

The aim of the present prospective study is to further develop and validate a composite risk score predicting both ischemic and bleeding risk, based on epidemiologic, clinical, biological, and/or morphologic complementary data. First, the investigators will assess the predictive performance of current clinical risk scores. Second, the investigators will assess …

fibrillation
electrocardiogram
  • 6 views
  • 15 May, 2022
  • 2 locations